Akèy › Miasteni grav › New York
Etid klinik pou Miasteni grav nan New York
13 etid pou Miasteni grav ap chèche patisipan nan sit nan New York.
Vil nan New York
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Mg0038 10106, Amherst
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07463521Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Equity Medical, New York
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT07217587ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Dent Neurologic Institute - Amherst, Amherst
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07673627ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Dent Neurologic Institute - Amherst, Amherst
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Dent Neurologic Institute - Amherst, Amherst
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07284420A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, New York
- TG Therapeutics Investigational Trial Site, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06680037A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Columbia University Irving Medical Center, New York
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Aug 14, 2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Columbia University, New York
- University of Rochester Medical Center, Rochester
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Aug 13, 2026 · NCT06359041Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1036, New York
- Site Number - 1034, New York
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT07039916A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- Hospital for Special Surgery, New York
- Mount Sinai Health System, New York
- Montefiore Medical Center, The Bronx
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Columbia University Irving Medical Center, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, New Hyde Park
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 18, 2026 · NCT04202341The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
- Neurological Associates of Long Island, P.C., Lake Success
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Apr 11, 2025 · NCT05564936Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.